HRT Financial Sells Shares of Aditxt, Inc. (ADTX)
HRT Financial LP sold over 3 million shares of Aditxt, Inc. as the stock trades near its 52-week low.
Key Points
- HRT Financial LP sold 3,132,480 shares of Aditxt, Inc. on June 16, 2026, valued at approximately $31,324.80.
- Aditxt, Inc., a biotech company on NasdaqCM, is trading near its 52-week low of $0.00 with a market cap of $3,263.
- Insider transactions show HRT Financial LP was active in June 2026, buying and selling millions of shares within days.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HRT Financial LP made a notable move in its holdings of Aditxt, Inc. (NasdaqCM: ADTX) by selling 3,132,480 shares on June 16, 2026. This transaction was valued at approximately $31,324.80, with each share priced at about $0.01. The sale comes as Aditxt's stock trades near its 52-week low of $0.00.
What Changed in HRT Financial's Aditxt Position
HRT Financial LP's decision to sell over 3 million shares of Aditxt represents a significant reduction in its position. The sale was not part of a pre-planned trading program, indicating a strategic choice by the firm. Prior to this sale, HRT Financial had been active in acquiring shares, including a purchase of 2,114,344 shares on June 15, 2026.
Other Institutional Activity in Aditxt
Several other institutional investors also adjusted their positions in Aditxt. Geode Capital Management, LLC added 434 shares, bringing its total to 434 shares valued at approximately $11,472. Morgan Stanley increased its holdings by 296 shares, ending with 296 shares worth about $7,833. Tower Research Capital LLC reduced its stake by 15 shares, holding 20 shares valued at $535. UBS Group AG exited its position entirely, selling all 23 shares it previously held.
Aditxt, Inc. Stock Up 42.9%
Shares of Aditxt, Inc. are trading near $0.00 on the Nasdaq Capital Market. The company has a market capitalization of approximately $3,263 and a forward P/E ratio that isn't meaningful due to its lack of profitability. Aditxt's stock has seen a 52-week high of $53,453.52, highlighting significant volatility. The 50-day and 200-day moving averages are $4.16 and $3,857.65, respectively.
$ADTX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Aditxt reported revenue of $14,336 with a growth rate of 10.94%. However, the company is not currently profitable, with an EPS of -$1,380.80 and a net margin of 0.0%. The next earnings report is anticipated on August 18, 2025.
Insider Buying and Selling at Aditxt, Inc.
In addition to HRT Financial's activity, DRW Securities, LLC sold 126,772 shares on June 17, 2026, at a price of $0.01 per share. Earlier in the month, HRT Financial LP bought 4,252,767 shares on June 12, 2026, at $0.02 each, indicating a pattern of active trading within a short period.
Analysts Set New Price Targets
On September 6, 2023, H.C. Wainwright reiterated its buy rating for Aditxt with a price target of $61. The analyst consensus provides a positive outlook, though the stock's current trading price remains significantly lower.
About Aditxt, Inc.
Aditxt, Inc., headquartered in Mountain View, California, operates in the biotechnology sector. The company focuses on developing biopharmaceutical products that help individuals understand and manage their immune profiles. Their technologies include AditxtScore and FlowSpot, which provide insights into immune system activity. Aditxt also develops therapies for conditions like psoriasis and type-1 diabetes and offers diagnostic tests for early cancer detection. The company was formerly known as ADiTx Therapeutics, Inc. and rebranded in 2021.
Bottom Line
HRT Financial LP's recent sale of Aditxt shares reflects active portfolio management amid the company's volatile stock performance. Investors keep an eye on such filings to gauge institutional sentiment, though these backward-looking reports may not represent current positions. Aditxt's focus on innovative biopharmaceutical solutions makes it a company to watch in the evolving healthcare landscape.
Get Aditxt, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ADTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.